GSE252944 AKT inhibition 10 v 13 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE252944_AKT inhibition_10_v_13_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE252944_AKT inhibition_10_v_13_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE252944_AKT inhibition_10_v_13_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE252944_AKT inhibition_10_v_13_human_up.

Results found

Linked to

 

Label

Description

 

Gene

H2A clustered histone 19

Gene

OIP5 antisense RNA 1

Gene

cutA divalent cation tolerance like, pseudogene

Gene

CTBP1 divergent transcript

Gene

long intergenic non-protein coding RNA 1116

Gene

negative regulator of antiviral response

Gene

GAS6 divergent transcript

Gene

ELFN1 antisense RNA 1

Gene

SDHA pseudogene 4

Gene

hydroxysteroid 17-beta dehydrogenase 7 pseudogene 2

  • Gene

    H2A clustered histone 19


  • Gene

    OIP5 antisense RNA 1


  • Gene

    cutA divalent cation tolerance like, pseudogene


  • Gene

    CTBP1 divergent transcript


  • Gene

    long intergenic non-protein coding RNA 1116


  • Gene

    negative regulator of antiviral response


  • Gene

    GAS6 divergent transcript


  • Gene

    ELFN1 antisense RNA 1


  • Gene

    SDHA pseudogene 4


  • Gene

    hydroxysteroid 17-beta dehydrogenase 7 pseudogene 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.